Clinical trial NCT03512262 - References

Osteoporosis — Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

Citation(s)

•   Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R
  Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993 Dec;14(6):690-709. doi: 10.1210/edrv-14-6-690. No abstract available. Erratum In: Endocr Rev 1994 Apr;15(2):261.
•   Mannstadt M, Juppner H, Gardella TJ
  Receptors for PTH and PTHrP: their biological importance and functional properties. Am J Physiol. 1999 Nov;277(5):F665-75. doi: 10.1152/ajprenal.1999.277.5.F665.
•   Rizzoli R, Bonjour JP, Ferrari SL
  Osteoporosis, genetics and hormones. J Mol Endocrinol. 2001 Apr;26(2):79-94. doi: 10.1677/jme.0.0260079.

A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis

Details for clinical trial NCT03512262